CS
NVLN

Credit Suisse’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Credit Suisse’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-32,137
Closed -$225K – 4310
2017
Q3 		$225K Buy
32,137
+7,418
+30% +$59.4K ﹤0.01% 3883
2017
Q2 		$228K Buy
24,719
+3,059
+14% +$29.5K ﹤0.01% 3580
2017
Q1 		$233K Sell
21,660
-6,726
-24% -$68.7K ﹤0.01% 3591
2016
Q4 		$239K Buy
+28,386
New +$251K ﹤0.01% 3746

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Credit Suisse's NVLN Position: Q4 2017 in Review

Credit Suisse sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2017, closing a stake of 32,137 shares — an estimated $225K sold.

Credit Suisse first reported a position in NVLN in Q4 2016 and held it in 4 quarters. The position peaked at $239K in Q4 2016. 82 funds tracked by Wall St. Rank hold NVLN as of Q4 2017.

  • Credit Suisse reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2017 after selling out during the quarter.
  • Credit Suisse sold 32,137 Novelion Therapeutics Inc. Common Shares shares in Q4 2017, an estimated $225K.
  • Credit Suisse first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 4 quarters.
  • Credit Suisse's Novelion Therapeutics Inc. Common Shares position peaked at $239K in Q4 2016.
  • 82 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2017.

Based on Credit Suisse's 13F filing for Q4 2017, filed 14 Feb 2018.